# Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

> **NCT05666804** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 148 (actual)

## Conditions studied

- Macular Polypoidal Choroidal Vasculopathy (PCV)

## Interventions

- **DRUG:** Brolucizumab 6mg
- **DRUG:** Brolucizumab 6mg

## Key facts

- **NCT ID:** NCT05666804
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-06
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05666804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05666804, "Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05666804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*